Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: Pancho Villa who wrote (960)	12/28/1997 5:05:00 PM
From: Andrew H	Respond to of 1359

>>High class Wall Street prostitution at its best.<< Hey, Pancho, this is unfair. Lehman's generally does excellent quality biotech analysis. IPIC does have good prospects from their two lead drugs. However, these prospects are less than certain. These two drugs, IMHO, make a short position risky. I also agree that the liability issue makes a long position in this stock too risky at this time. As the analyst said, there will be a shadow over this company for a long time.